Convergent Dental Inc., a privately held dental device company, announced software upgrades to the company’s flagship product Solea®, the first FDA cleared CO2 9.3 micron dental laser for hard, soft, and osseous tissue procedures. The dental laser’s most recent updates include new 1.25mm and 0.75mm-XC spot sizes. Multiple spot sizes are exclusive to Solea and driven by Solea’s unique computer controls that are a major factor in the laser’s industry leading performance. The new spot sizes continue to enhance Solea’s versatility, increasing cutting speed and precision and making it even easier to deliver anaesthesia-free, blood-free and pain-free experiences. Convergent Dental will showcase Solea’s latest spot sizes at the Chicago Dental Society Midwinter Meeting 2016 at the McCormick Place West, Chicago, IL from February 25 to 27, 2016.
“Convergent Dental’s updates have consistently increased the value I get from my Solea since I purchased it,” said Dr. Joshua Weintraub, DDS. “Other companies require you to purchase an entirely new system to receive the performance improvements that I simply download over Wifi for my Solea. I don’t know any other company in dentistry that works that way to improve their product so seamlessly.”
Enhancements to spot sizes and the ability for dentists to simply download them when available, underscores the uniqueness of this system. Solea’s one-of-a-kind wavelength combined with the software algorithms that drive it, are what enables Solea to be the first and only dental laser that can be used reliably anaesthesia-free and blood-free by ordinary, everyday dentists.
“This update and the new spot sizes it provides are part of a continuous improvement strategy that we have been delivering on since we introduced Solea two years ago,” said Convergent Dental CEO Michael Cataldo. “Our customers have come to expect this from us as part of the high level of service and that we deliver with Solea. We believe that our commitment to this strategy will pay dividends for us, our customers and their patients long into the future.”